Moore DJ, Jain S, Dub? MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis. 2018 05 02; 66(10):1566-1572.
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
Hassan A, Blumenthal JS, Dube MP, Ellorin E, Corado K, Moore DJ, Morris SR
Effect of rectal douching/enema on rectal gonorrhoea and chlamydia among a cohort of men who have sex with men on HIV pre-exposure prophylaxis. Sex Transm Infect. 2018 11; 94(7):508-514.
Effect of rectal douching/enema on rectal gonorrhoea and chlamydia among a cohort of men who have sex with men on HIV pre-exposure prophylaxis.
Khan S, Funk CA, Corado K, Morris S, Dube MP
Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis. 2017; 4(3):ofx149.
Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis.
Hassan A, Wertheim JO, Blumenthal JS, Ellorin E, Dube MP, Corado K, Moore DJ, Morris SR
Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. Medicine (Baltimore). 2019 Dec; 98(50):e18232.
Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners.
Pasipanodya EC, Li MJ, Jain S, Sun X, Tobin J, Ellorin E, Dube M, Daar ES, Corado K, Milam J, Blumenthal J, Morris SH, Moore DJ, and the California Collaborative Treatment Group (CCTG)
Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men. AIDS Behav. 2020 Nov; 24(11):3192-3204.
Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men.
Watson CW, Pasipanodya E, Savin MJ, Ellorin EE, Corado KC, Flynn RP, Opalo C, Lampley E, Henry BL, Blumenthal J, Bolan R, Morris S, Moore DJ
AIDS education and prevention : official publication of the International Society for AIDS Education
Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California. AIDS Educ Prev. 2020 12; 32(6):472-485.
Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California.
Blumenthal J, Jain S, He F, Amico KR, Kofron R, Ellorin E, Stockman JK, Psaros C, Ntim GM, Chow K, Anderson PL, Haubrich R, Corado K, Moore DJ, Morris S, Landovitz RJ
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021 10 05; 73(7):1149-1156.
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Blumenthal J, Landovitz R, Jain S, He F, Kofron R, Ellorin E, Ntim GM, Stockman JK, Corado K, Rivet Amico K, Moore DJ, Morris S
Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. AIDS Patient Care STDS. 2021 12; 35(12):481-487.
Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.
Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It? JAMA. 2016 Jul 12; 316(2):149-51.
Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?
Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opin Pharmacother. 2017 Mar; 18(4):427-432.
Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opin Pharmacother. 2018 04; 19(6):589-596.
Next generation fixed dose combination pharmacotherapies for treating HIV.
Corado K, Jain S, Morris S, Dube MP, Daar ES, He F, Aldous JL, Sitapati A, Haubrich R, Milam J, Karris MY
Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594. AIDS Behav. 2018 Aug; 22(8):2698-2710.
Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594.
Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, Dube MP, Daar ES, Morris SR, Moore DJ, California Collaborative Treatment Group (CCTG) TAPIR Study Team
Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. J Infect Dis. 2018 10 05; 218(10):1551-1559.
Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men.
Milam J, Jain S, Dub? MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR, CCTG Team
Journal of acquired immune deficiency syndromes (1999)
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):e9-e13.
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.
Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dub? MP, Morris S, California Collaborative Treatment Group 595 Team
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerg Infect Dis. 2018 12; 24(12).
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.
Two-drug regimens for treatment of na?ve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018; 12:3731-3740.
Two-drug regimens for treatment of na?ve HIV-1 infection and as maintenance therapy.
Hoenigl M, Hassan A, Moore DJ, Anderson PL, Corado K, Dub? MP, Ellorin EE, Blumenthal J, Morris SR, California Collaborative Treatment Group (CCTG) 601 Team
Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2019 06 01; 81(2):166-174.
Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men.
Nanayakkara DD, Sun X, Morris S, Louie S, Mulligan K, Overton T, Asante I, Corado K, Jain S, Dub? MP
Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men. AIDS Res Hum Retroviruses. 2019 07; 35(7):608-614.
Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men.
Blumenthal J, Moore DJ, Jain S, Sun X, Ellorin E, Corado K, Hoenigl M, Dube M, Haubrich R, Morris SR
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. AIDS Patient Care STDS. 2019 05; 33(5):220-226.
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men.
Daar ES, Rosen MI, Wang Y, Siqueiros L, Shen J, Guerrero M, Xiong D, Dao J, Young T, Corado K, Fletcher CV, Liu H
Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. Clin Transl Sci. 2020 01; 13(1):189-194.
Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study.
Bristow CC, Hassan A, Moore DJ, Dub? MP, Corado K, Chow K, Ellorin E, Blumenthal J, Morris SR, CCTG Team
Sexually transmitted infections among participants in an HIV PrEP adherence trial. Int J STD AIDS. 2022 03; 33(4):397-403.
Sexually transmitted infections among participants in an HIV PrEP adherence trial.
Hassan A, Agustin HGS, Burke L, Kofron R, Corado K, Bolan R, Landovitz RJ, Dub? MP, Morris SR
Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California. J Viral Hepat. 2022 07; 29(7):529-535.
Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California.
Storholm ED, Huang W, Ogunbajo A, Horvath KJ, Reback CJ, Blumenthal J, Moore DJ, Flynn RP, Bolan RK, Corado KC, Morris SR
Gender-Based Violence and Post-traumatic Stress Disorder Symptoms Predict HIV PrEP Uptake and Persistence Failure Among Transgender and Non-binary Persons Participating in a PrEP Demonstration Project in Southern California. AIDS Behav. 2023 Feb; 27(2):745-759.
Gender-Based Violence and Post-traumatic Stress Disorder Symptoms Predict HIV PrEP Uptake and Persistence Failure Among Transgender and Non-binary Persons Participating in a PrEP Demonstration Project in Southern California.
Morris SR, Jain S, Blumenthal J, Bolan R, Dub? MP, Henderson P, Corado K, Sun S, He F, Chow K, Burke L, Anderson PL, Moore DJ
Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):453-459.
Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study.
Liu H, Wang Y, Huang Y, Xiong D, Shen J, Siqueiros L, Bala V, Savage GM, Guerrero M, Corado K, Rosen MI, Fletcher CV, Daar ES
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial. EBioMedicine. 2022 Dec; 86:104330.
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial.
Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ, ACTIV-2/A5401 Study Team
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024; 9(1):138-155.
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.
Charles R. Drew University of Medicine and Science